All In Biotech

Drug Trial Radar · NCT03392116

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM120 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

92

Actual

Start

Jan 29, 2018

Primary completion

Jan 14, 2019

Study completion Mar 11, 2019

Sponsor

Lead sponsor
NGM Biopharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Jan 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects

Conditions

  • Cachexia

Interventions

  • NGM120Biological

    Subcutaneous Injection

  • PlaceboOther

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A Arm-Single Dose: Treatment Emergent Adverse eventsTime frame: 28 days
  2. Part B Arm-Multiple Dose: Treatment Emergent Adverse eventsTime frame: 84 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Limited

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.